Data from Pharmexcil, a government body created for the promotion of Indian pharmaceutical exports shows that Indian companies made the most drug master filings or registrations of bulk drugs in the US (for all non-pharma types, bulk drugs are the key ingredients that lend the medicines their potency and are finished into capsules, and syrups).
India filed 2101 so-called ‘active’ DMFs (those currently in use) accounting for 29.25 per cent of all such filings. US companies with a 15.62 per cent share are a distant second. China places at number four with 9.23 per cent.
Among the Indian companies, Dr Reddy’s filed the most followed by Aurobindo and Cipla.
The US FDA, which opened an office in New Delhi early last year, wasn’t a moment too soon, it appears.
|Global DMF (Type II active)*|
|Country||No. of DMFs||% share|
*as of September 30, 2009